BRIACELL THERAPEUTICS -CW27 (BCTXW)

0.2899  +0.02 (+6.46%)

After market: 0.24 -0.05 (-17.21%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

BRIACELL THERAPEUTICS -CW27

NASDAQ:BCTXW (11/14/2024, 8:05:26 PM)

After market: 0.24 -0.05 (-17.21%)

0.2899

+0.02 (+6.46%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorN/A
GICS IndustryN/A
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-50.91%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap0
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

BCTXW Daily chart

Company Profile

BriaCell Therapeutics Corp. is an immuno-oncology focused biotechnology company. It developed a patented whole-cell vaccine, cancer immunotherapy technology called the `BriaVax` vaccine for cancer. The company's technology consists of Bria-IMT(TM), Bria-OTS(TM) and BriaDx(TM) which are in clinical stage. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Company Info

BRIACELL THERAPEUTICS -CW27

BCTXW News

ChartMill News Image17 hours ago - ChartmillCurious about what's happening in today's session? Check out the latest stock movements and price changes.

Which stocks are experiencing notable movement on Thursday?

ChartMill News Image20 hours ago - ChartmillWhich stocks are moving on Thursday?

Let's have a look at the top gainers and losers in the middle of the day of today's session.

News Image7 days ago - BriaCell Therapeutics Corp.BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference

BriaCell’s clinical candidates for next generation breast cancer (Bria-BRES+™) and prostate cancer (Bria-PROS+™) generate robust anti-cancer activity in...

News Image11 days ago - BriaCell Therapeutics Corp.BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13

Five BriaCell poster presentations to highlight updated survival and key biomarker data from Phase 2 trial of Bria-IMT™ plus immune check point inhibitor...

News Image24 days ago - BriaCell Therapeutics Corp.BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data

55% of BriaCell patients1 remained alive one year since enrollment in BriaCell’s Phase 2 study, markedly exceeding the survival rate of current standard of...

News Imagea month ago - BriaCell Therapeutics Corp.BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study

35 sites active and enrolling in pivotal Phase 3 study of Bria-IMT™ combination with immune check point inhibitor in metastatic breast cancer (MBC)Primary...

BCTXW Twits

Here you can normally see the latest stock twits on BCTXW, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example